Почетна › Метастатски карцином › Masachuset › Boston
Kliničke studije za Метастатски карцином u gradu Boston, MA
Jedna studija za Метастатски карцином traži učesnike na lokaciji u gradu Boston ili u blizini. Otvorite je da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Тражи се учесникФаза 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Тражи се учесникФаза 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital (MG), Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Тражи се учесникФаза 3
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Boston Medical Center, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Тражи се учесникФаза 2/3
- Dana-Farber Cancer Institute, Boston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Тражи се учесникФаза 1
- Research Site, Boston
- Research Site, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Тражи се учесник
- Massachusetts General Hospital, Boston
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Тражи се учесникФаза 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Тражи се учесникФаза 1
- Mass General Cancer Center, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Тражи се учесникФаза 3
- Massachusetts General Hospital Cancer Center, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Тражи се учесникФаза 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Тражи се учесникФаза 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Тражи се учесникФаза 3
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Тражи се учесникФаза 1/2
- Avenzo Therapeutics Recruiting Site, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute., Boston
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Тражи се учесникФаза 1/2
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Тражи се учесникФаза 1/2
- Massachusetts General Hospital - Main Campus, Boston
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of PYX-201 in Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Тражи се учесникФаза 2
- I-Mab Site 1002, Boston
Remote Monitoring and Symptom Management Digital Application
Тражи се учесник
- Massachusetts General Hospital, Boston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Тражи се учесникФаза 2/3
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Тражи се учесникФаза 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Тражи се учесникФаза 2/3
- Massachusetts General Hospital, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Mass General Hospital, Boston
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
Тражи се учесникОпсервациона студија
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Тражи се учесникЗдраве особе су добродошле
- Dana Farber Cancer Institute, Boston
Studije za Метастатски карцином u drugim gradovima
- Houston, TX100 студија
- New York City, NY93 студија
- Nashville, TN69 студија
- Los Angeles, CA57 студија
- Arlington, VA52 студија
- St. Louis, MO52 студија
- San Antonio, TX44 студија
- Washington, DC44 студија
- Dallas, TX44 студија
- Philadelphia, PA42 студија
- Chicago, IL42 студија
- Seattle, WA39 студија
Ostale studije u gradu Boston
- Рак дојке110 студија
- Рак (све врсте)90 студија
- Немалоклетни карцином плућа87 студија
- Рак плућа63 студија
- Колоректални карцином62 студија
- Рак јајника62 студија
- Рак простате56 студија
- Карцином ендометријума51 студија
- Депресија50 студија
- Затајење срца46 студија
- Многи мијелом45 студија
- Akutna mijeloidna leukemija44 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.